China Health Group Inc. Announces New AI-Driven Clinical Research Focus and Exclusive Rights for Innovative Dementia Treatment
Reuters
Sep 15
<a href="https://laohu8.com/S/CHHE">China Health</a> Group Inc. Announces New AI-Driven Clinical Research Focus and Exclusive Rights for Innovative Dementia Treatment
China Health Group Inc. has announced the successful hosting of the "AI-RWS Real-World Study Summit Forum" in Shanghai. During the event, more than ten AI-driven real-world study (AI-RWS) projects were discussed. The Group plans to develop a world database in China that will include 100,000 patients over the next five years. The focus will be on researching non-pharmacological interventions and combination therapies, providing crucial data for innovative drug registration and post-marketing safety re-evaluation. The Group holds exclusive rights in China for clinical research experiments involving Xienka Microchip Nanoparticles and Xienmei Flash Tablets. Xienka Microchip Nanoparticles, a key product in this research, is designed for the treatment of mild to moderate dementia and is covered by national medical insurance. The results of these studies were not specified to be presented at the forum, indicating they may be shared in future updates.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Health Group Inc. published the original content used to generate this news brief on September 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.